Health Care Costs Associated With Muscle Weakness: A UK Population-Based Estimate

Abstract

Sarcopenia and muscle weakness are responsible for considerable health care expenditure but little is known about these costs in the UK. To address this, we estimated the excess economic burden for individuals with muscle weakness regarding the provision of health and social care among 442 men and women (aged 71–80 years) who participated in the Hertfordshire Cohort Study (UK). Muscle weakness, characterised by low grip strength, was defined according to the Foundation for the National Institutes of Health criteria (men < 26 kg, women < 16 kg). Costs associated with primary care consultations and visits, outpatient and inpatient secondary care, medications, and formal (paid) as well as informal care for each participant were calculated. Mean total costs per person and their corresponding components were compared between groups with and without muscle weakness. Prevalence of muscle weakness in the sample was 11%. Mean total annual costs for participants with muscle weakness were £4592 (CI £2962–£6221), with informal care, inpatient secondary care and primary care accounting for the majority of total costs (38%, 23% and 19%, respectively). For participants without muscle weakness, total annual costs were £1885 (CI £1542–£2228) and their three highest cost categories were informal care (26%), primary care (23%) and formal care (20%). Total excess costs associated with muscle weakness were £2707 per person per year, with informal care costs accounting for 46% of this difference. This results in an estimated annual excess cost in the UK of £2.5 billion. Electronic supplementary material The online version of this article (10.1007/s00223-018-0478-1) contains supplementary material, which is available to authorized users.

Efficacy of School-Based Interventions for Improving Muscular Fitness Outcomes in Adolescent Boys: A Systematic Review and Meta-analysis

“…Despite the growing body of literature supporting the benefits of MF, it is often the overlooked element of PA guidelines. Recent UK estimates for health care costs associated with muscle weakness, defined by low grip strength according to the Foundation for the National Institutes of Health criteria (men < 26 kg, women < 16 kg), exceed £2.5 billion [27]. Furthermore, the United States reported estimated health care costs associated with muscular weakness at $18.5 billion [28].…”

Osteosarcopenia: epidemiology, diagnosis, and treatment—facts and numbers

“…In 2010 alone, there was a respective 5.5 and 22 million men and women living with osteoporosis in the European Union, resulting in roughly 3.5 million fragility fractures and costing over €37 billion, a figure that is projected to increase by 25% in 2025. Likewise, using longitudinal data from the Hertfordshire trial, muscle weakness (characterized by low grip strength) was associated with an annual cost of £2,707 per person in the UK, with an overall estimated cost of £2.5 billion in 2018 . Alarmingly, the aging population is now ‘moving less and eating more’ in community‐dwelling and aged‐care facilities, enabling a trend towards an MSK phenotype with low bone and muscle mass and increased ectopic fat, which may manifest as osteosarcopenia …”

Expert’s Choice: 2018’s Most Exciting Research in the Field of Pediatric Exercise Science

“…School care and health care should focus on the identification and treatment of youth with muscle weakness and should recognize muscle strength as a biomarker of health. At present, modern-day youth are less active, more obese, and weaker than past generations, and it is likely that the economic burden of managing health complications arising from already existing disease will continue (125,165). A take home message is that the handgrip strength or standing long jump has the potential to be used as a simple and inexpensive screening tool to alter the current trajectory toward physical inactivity and related comorbidities.…”